Table 6.
Average treatment effect of PBF in the South
| Indicator | Category | Level of effort | Price | Quarterly average effect per facility (standard error) | Magnitude (% change of baseline) | Onset of effect | Responsiveness score |
|---|---|---|---|---|---|---|---|
| High responsiveness | |||||||
| HIV-infected pregnant women who initiated ART | PMTCT | Low | $10 | 19.4*** (3.8) | 194.6 | Delayed | 2 |
| HIV-infected women who received a FP consultation and a modern contraceptive method | PMTCT | Low | $5 | 58.8*** (12.4) | 221.7 | Delayed | 2 |
| Pregnant women who completed four ANC visits | MCH | Low | $2 | 88.6*** (15.1) | 82.4 | Delayed | 1.67 |
| Medium responsiveness | |||||||
| HIV-infected children 0–23 months of age who initiated ART treatment for the first time | Paediatric HIV | High | $7.70 | 3.2*** (0.6) | 45.2 | Delayed | 1.33 |
| Children, born to HIV-infected women, who were tested via rapid test for HIV 9–12 months after birth | Paediatric HIV | Low | $4.20 | 12.2*** (3.1) | 54.6 | Delayed | 1.17 |
| Children, born to HIV-infected women, who were tested (PCR) for HIV between 4 and 8 weeks age | Paediatric HIV | Medium | $4.90 | 17.2*** (2.2) | 53.3 | Delayed | 1.17 |
| Children with acute malnutrition who completed treatment and satisfied the defined clinical criteria for discharge | MCH | Medium | $1.50 | 4.0** (1.4) | 64.6 | Delayed | 0.87 |
| HIV-infected children 0–14 years of age alive 12 months after initiating ART | Paediatric HIV | High | $11.20 | 4.2***(0.94) | 34.5 | Delayed | 0.83 |
| Low responsiveness | |||||||
| Post-natal consultations 3–28 days after birth | MCH | Medium | $1.60 | 40.7* (17.2) | 24.8 | Delayed | 0.53 |
| Unresponsive Indicators | |||||||
| Women, excluding HIV-infected women, who received a FP consultation and a modern contraceptive method | MCH | Low | $0.10 | – | – | – | 0 |
| HIV-infected pregnant women who received ARV to reduce mother-to-child transmission | PMTCT | Low | $6.25 | – | – | – | 0 |
| HIV-infected patients who initiated Isoniazid to prevent TB | Adult HIV/TB | Medium | $2 | – | – | – | 0 |
| HIV-infected children 2–14 years of age who initiated ART treatment for the first time | Paediatric HIV | High | $7 | – | – | – | 0 |
| Facility deliveries | MCH | Low | $3 | – | – | – | 0 |
| Children who received full vaccination for BCG, DPT, polio and measles in the first 9 months | MCH | Low | $1.80 | – | – | – | 0 |
| HIV-infected adults (>15 years) alive 12 months after initiating ART | Adult HIV/TB | High | $8 | – | – | – | 0 |
| HIV-infected adults (excluding pregnant women) who initiated ART treatment for the first time | Adult HIV/TB | High | $4 | – | – | – | 0 |
| Adults co-infected with HIV and TB who initiated ART treatment for the first time | Adult HIV/TB | High | $2.80 | – | – | – | 0 |
Note: BCG: Bacille Calmette-Guerin; DPT: Diphtheria, tetanus, and pertussis vaccine; PCR: polymerase chain reaction.
Level of significance: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001
Prices are reflective of quarter 11